The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Gov. Ned Lamont signed Public Act 25-167 into law July 30. Its aim is to implement the task force’s recommendations in an effort to reduce the cost of prescription drugs for individuals and the state ...

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

On Tuesday, Federal Court Judge Mitchell Goldberg issued a ruling that is the second staggering decision against Woonsocket-based CVS in recent weeks. Whistleblowers brought the two cases alleging ...

Caremark was found liable in June, and Philadelphia federal court Chief Judge Mitchell Goldberg ordered the company to pay $95 million in damages, deferring final rulings on penalties.

With many PBMs under scrutiny, smaller startups that bill themselves as transparent are seeing interest from employers.

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

A federal judge has ordered CVS Caremark to pay nearly $290 million in damages after determining the pharmacy benefit manager overbilled Medicare for prescription drugs, according to court documents ...